Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials

Journal of Cellular Biochemistry

Volumn 63, Issue SUPPL. 25, 1996, Pages 156-164

  Bostwick, David G ^a   Aquilina, Joseph W ^a  

^a MAYO CLINIC   (United States)

Author keywords

carcinogenesis; chemoprevention; prostate cancer; prostatic intraepithelial neoplasia; prostatic neoplasms; surrogate endpoint biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CANCER PREVENTION; CHROMOSOME 8; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA CONTENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEEDLE BIOPSY; ONCOGENE C ERB; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK FACTOR; CELL DIVISION; CHEMISTRY; CHEMOPROPHYLAXIS; FLUORESCENCE IN SITU HYBRIDIZATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PRECANCER; PROGNOSIS; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW;

BIOLOGICAL MARKERS; CELL DIVISION; CHEMOPREVENTION; CHROMOSOMES, HUMAN, PAIR 8; CLINICAL TRIALS; DNA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOVASCULARIZATION, PATHOLOGIC; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 0030513962     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(1996)25+<156::AID-JCB22>3.0.CO;2-L     Document Type: Article

References (59)

1. Bostwick DG (1995): High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer. Cancer 75:1823-1836.
2. Davidson D, Bostwick DG, Quian J-Q, Wollan PC, Oesterling JE, Rudders RA, Siroky M, Stilmant M (1995): Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: Predictive accuracy in needle biopsies. J Urol 154:1295-1299.
3. Sporn MB, Dunlop NM, Newton DL, Smith M (1976): Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation Proc 35:1332-1338.
4. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Cavey JM, Doody LA, Knapp GG, Nayfield S, Parkinson DR, Prasad VK, Prorok PC, Sausville EA, Sigman CC (1994): Strategy and planning for chemopreventative drug development: Clinical development plans. J Cell Biochem 20 (Suppl):55-62.
5. Benner SE, Lippman SM, Hong WK (1995): Chemoprevention of head and neck cancer. In Nixon DW (ed): "Chemoprevention of Cancer." Boca Raton: CRC Press, pp 121-134.
6. McNeal JE, Bostwick DG (1986): Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 17:64-71.
7. Bostwick DG, Brawer MK (1987): Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59:788-794.
8. Davidson D, Siroky M, Rudders R, Qian J, Bostwick DG, Stilmant M (1994): Prostatic intraepithelial neoplasia is predictive of adenocarcinoma. Mod Pathol 7:72A.
9. Bostwick DG, Qian J, Frankel K (1995): The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 154:1791-1794.
10. Mettlin C, Lee F, Drago J, Murphy GP (1991): The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 67:2949-2958.
11. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG (1994): Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44:91-95.
12. Bostwick DG, Burke HB, Wheeler TM, Chung LWK, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, Grizzle WE, Grignon DJ (1994): The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem 19 (Suppl):283-289.
13. Montironi R, Magi Galluzzi CM, Diamanti L, Giannulis I, Pisani E, Scarpelli M (1993): Prostatic intra-epithelial neoplasia. Expression and location of proliferating cell nuclear antigen in epithelial, endothelial and stromal nuclei. Virchow Arch [A] Pathol Anat Histopathol 422:185-192.
14. Jones EC, McNeal J, Bruchovsky N, de Jong G (1990): DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason Grade 4 and 5, and lymph node metastases. Cancer 66:752-757.
15. Konchuba AM, Schellhammer PF, Kolm P, Clements MA, Wright GL Jr (1993): Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens - Relationship to serum prostate-specific antigen and prostatic acid phosphatase, clinical stage and histopathology. J Urol 150:115-119.
16. Wu WJ, Huang MS, Wang HJ, Chiang PH, Huang CH, Chiang CP (1993): Flow cytometric DNA analysis of advanced prostatic adenocarcinoma. Kao-Hsiung I Chih 9:122-130.
17. Al-Abadi H, Nagel R (1992): Nuclear DNA analysis: DNA heterogeneity in the monitoring of patients with locally advanced prostatic carcinoma. Eur Urol 22:303-310.
18. Nielsen K, Overgaard J, Bentzen SM, Bruun E (1993): Histological grade, DNA ploidy and mean nuclear volume as prognostic factors in prostatic cancer. APMIS 101:614-620.
19. Humphrey PA, Walther PJ, Currin SM, Volmer RT (1991): Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. Am J Surg Pathol 15:1165-1170.
20. Anscher MS, Prosnitz LR (1991): Multivariate analysis of factors predicting local relapse after radical prostatectomy - Possible indications for postoperative radiotherapy. Int J Rad Oncol 21:941-947.
21. Wirth MP, Muller HA, Manseck A, Muller J, Frohmuller HGW (1991): Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy. Eur Urol 20:248-252.
22. Voges GE, Eigner EB, Ross W, Sussman H, Stockle M, Freiha FS, Stamey TA (1993): Pathologic parameters and flow cytometric ploidy analysis in predicting recurrence in carcinoma of the prostate. Eur Urol 24:132-139.
23. Van den Ouden D, Tribukait B, Blom JH, Fossa SD, Kurth KH, Ten Kate FJ, Heiden T, Wang N, Schroder FH (1993). Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression. J Urol 150:400-406.
24. Forsslund G, Esposti P-L, Nilsson B, Zetterberg A (1992): The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 69:1432-1439.
25. Nativ O, Winkler HZ, Raz Y, Therneau TM, Farrow GM, Myers RP, Zincke H, Lieber MM (1989): Stage C prostatic adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc 64:911-919.
26. Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, Therneau TM, Lieber MM (1990): Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg 125:327-331.
27. DeVere White RW, Deitch AD, Meyer-Haass GM, Siders DB, Lee F (1992): Deoxyribonucleic acid ploidy in the irradiated prostate. World J Urol 10:173-178.
28. Shankey TV, Kallioniemi O-P, Koslowski JM, Lieber MM, Mayall BH, Miller G, Smith GJ (1993): Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 14:497-500.
29. Takai K, Goellner JR, Katzmann JA, Myers RP, Lieber MM (1994): Static image and flow DNA cytometry of prostatic adenocarcinoma: Studies of needle biopsy and radical prostatectomy specimens. J Urol Pathol 2: 39-48.
30. Warzynski MJ, Soechtig CE, Maatman TJ, Goldsmith LC, Carothers GG (1994): DNA analysis by flow cytometry of paraffin embedded core biopsies of the prostate. Prostate 24:313-319.
31. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC (1992): Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5:320-327.
32. Ibrahim GK, MacDonald JA, Kerns BJM, Kerns B-JM, Ibrahim SN, Humphrey PA, Robertspm CN (1992): Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues Surg Oncol 1:151-155.
33. Giri DK, Wadhwa SN, Upadhaya SN, Talwar GP (1993): Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: An immunohistochemical study. Prostate 23:329-336.
34. Visakorpi T, Kallioniemi O-P, Koivula T, Harvey J, Isola J (1992): Expression of epidermal growth factor receptor and ERBB2 (HER-2/neu) oncoprotein in prostatic carcinomas. Mod Pathol 5:643-648.
35. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN (1990): c-erbB-2 Oncoprotein expression in primary human tumors. Cancer 65:88-92.
36. Ware JL, Maygarden SJ, Koontz WW Jr, Strom SC (1991): Immunohistochemical detection of c-er6B-2 pro tein in human benign and neoplastic prostate. Hum Pathol 22:254-259.
37. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW (1993): Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150: 1427-1433.
38. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, Nobel M (1993): Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer, J Urol 150:126-131
39. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, Coffey DS (1994): Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem 19 (Suppl): 249-258.
40. Ross JS, Nazeer T, Church K, Amato C, Pigge H, Rifkin MD, Fisher HAG (1993): Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72:3020-3028.
41. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE (1994): Expression of p160erebB-3 and p185er6B-2 in prostatic intraepithelial neoplasia and prostatic adeno-carcinoma. J Natl Cancer Inst 86:1140-1145.
42. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH (1992): Infrequent RAS oncogene mutations in human prostate cancer. Prostate 20:327-333.
43. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC (1993): p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373.
44. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee W-H (1990): Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A 87:7762-7766.
45. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB (1994): Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 54:3574-3579.
46. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh E, Larson-Keller J, Lieber MM, Jenkins RB (1994): Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002.
47. Persons DL, Gibney DJ, Hatzmann JA, Lieber MM, Farrow GM, Jenkins RB (1993): Use of fluorescence in situ hybridization for deoxyribonucleie acid ploidy analysis of prostatic carcinoma. J Urol 150:120-125.
48. Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB (1994): Chromosomal aneusomies detected by fluorescence in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 152: 1157-1162.
49. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB (1995): Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414.
50. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM (.1995): Allelic loss on chromosome 8pl2-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959-2962.
51. MacGrogan D, Levy A, Bostwick D, Wagner M, Bookstein R (1994): Loss of chromosome arm 8p loci in prostate cancer' Mapping by quantitative alllic balance. Genes Chromosomes Cancer 10:151-159.
52. Bova GS, Carter BS, Bussemakers MJG, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB (1993): Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53: 3869-3873.
53. Bergerheim USR, Kunimi K, Collins VP, Ekman P (1991): Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer 3:215-220.
54. Moul JW, Kahn DG, Lewis DJ, Ho CK, Ross AA, McLeod DG (1994): Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: Correlation to preoperative serum prostate-specific antigen. Urology 43:68-73.
55. Gomella LG, White JL, McCue PA, Byrne DS, Mulholland SG (1993): Screening for occult nodal metastases in localized carcinoma of the prostate. J Urol 149:776-778.
56. Hamdy FC, Lawry J, Anderson JB, Parsons MA, Rees RC, Williams JL (1992): Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol 69:392-396.
57. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG (1992): Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112.
58. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R (1994): Molecular staging of prostate cancer with the use of an enhances reverse transcriptase-PCR assay. Urology 43:765-775.
59. Bostwick DG (1994): Target populations and strategies for chemoprevention trials of prostate cancer. J Cell Biochem 19 (Suppl):191-196.